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OBJECTIVES: To evaluate the cost-effectiveness of endovascular
repair (EVAR) compared to Open Surgery (OSR) for the treat-
ment of Abdominal Aortic Aneurysms (AAA) from the Italian
NHS’ perspective. METHODS: A Markov model was designed
to estimate the clinical and economic consequences of EVAR and
OSR after one year. The base case scenario refers to the treatment
of 70-year-old patients with AAA > 5.5 cm who are medically
suitable to undergo either OSR or EVAR. In the model, patients
move from one health state to another within 3- month cycles.
Transitional probabilities of the two treatment options, including
mortality and complications, as well as utilities were derived
from published sources. Cost input variables like resource utili-
zation during the procedure, treatment of post operative compli-
cations and cost of follow-up were estimated based on data
made available by a panel of Italian experts. RESULTS: Total
direct NHS costs were €15.858 and €12.289 for EVAR and
OSR, respectively. QALYs were 0.779 and 0.651 (EVAR vs OSR,
respectively). Results were evaluated at a 1-year timeframe. The
difference of costs due to systemic complications is favorable to
EVAR (€290/patient), whilst costs for EVAR-speciﬁc complica-
tions, like conversion to OSR, endoleak, rupture or endovascular
graft adjustment after migration, amount to €854/patient.
The ICER for EVAR vs OSR was estimated at €27.809/QALY.
Improvements in QoL, decrease of operative death and reduced
post operative complications with EVAR led to greater total
QALYs vs OSR. Sensitivity analysis conﬁrms base case scenario.
CONCLUSION: EVAR is a valuable alternative to OSR in 70
years old patients with AAA > 5.5. Efﬁcacious without compro-
mising QoL and with a safety decreasing the operative death,
EVAR can be considered a cost-effective procedure for AAA
in Italy.
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OBJECTIVES: To compare the resource use and subsequent
costs associated with types of major bleeds among hospitalised
acute coronary syndrome (ACS) patients. METHODS: Retro-
spective chart review was undertaken in Italy, France and Spain
of patients hospitalised for ACS and receiving antithrombotic,
antiplatelet or ﬁbrinolytic therapy to identify individuals with
retroperitoneal (RP), intracranial (IC), gastrointestinal (GI),
puncture site or excessive surgical bleeds requiring 2 or more
units of blood, or decrease in Hb > 3g/dL (DHb). Use of pro-
cedures and length of stay (LOS) were extracted from the
records. Publicly available country unit costs were applied to
estimate the cost of these major bleeds among ACS patients.
RESULTS: A total of 117 patient records were included, 63.2%
males, average age 74 years. Most patients were admitted for
ST-segment Elevation MI. The LOS by type of bleed was 9–14
days in Spain compared to 7–13 in Italy and 5–10 in France.
Only Spain identiﬁed records with bleed-related mortality.
Most days were in coronary care or intensive care units. For
procedures, CT scans were more common in Spain and ultra-
sound most common in France and Italy. Selected results show
an average LOS ranges between 9–14 days for DHb (total costs
€7097–9326); 9–13 days for transfusion (€8280–9105); 5–10
days for puncture site bleeds (€6182–10572). RP bleeds
resulted in 5–7 days (€5761–8080) and GI bleeds in 5–13 days
(€3906–9173). Overall average costs were €8341 for France,
€6730 for Italy and €8027 for Spain CONCLUSION: The most
frequently reported major bleeds in trials (DHb, puncture sites/
transfusions) are more costly than expected. Costs associated
with ACS-related bleeds vary by type and these speciﬁc costs
should be used in analyses.
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OBJECTIVES: Major bleeding during Acute Coronary Syn-
drome (ACS) hospitalization inﬂuences clinical outcomes but its
economic impact is unknown. This study estimates the costs
associated with managing major bleeds in ACS patients in the
hospital setting. METHODS: A retrospective chart review was
undertaken in 5 Spanish hospital to identify ACS patients with
the following bleeding events: intracranial haemorrhage (ICH),
retroperitoneal (RP) gastrointestinal (GI), puncture site or
excessive surgical bleeds (PSB), blood transfusion requiring 2 or
more units, or decrease in Hb > 3g/dL (DHb). Patient age,
reason for admission, extended length of stay (LOS) attributed
to the bleed, ward type, and resources to manage the bleed
were collected. RESULTS: Eighty-six patients were included
and analyzed (70% men), with a mean of age of 73.6 years (SD
10.9). The reasons for hospital admission were 10% non
ST-segment Elevation Myocardial Infarction (NSTEMI), 68%
ST-segment Elevation MI (STEMI) and 104% unstable angina
(UA) (8% not classiﬁed MI). The types of bleeds were 26% GI,
14% IC, 10% F, 26% DHb and 24% (transfusion). The most
common tests performed to were CT-Scan in 42%, Hb deter-
mination in 92% and red blood cell transfusions in 42% of the
included patients. The mean length of stay (LOS) was 14.7
across all patients. Extended 11.6 day mean LOS due to bleed.
The mean cost of all bleeding types was €8027. The mean cost
by type of bleeding was €1431 (F), €6337 (IC), €9105 (trans-
fusion), €9179 (GI) and €9326 (DHb). The cost increase was
caused by the increase in hospitalization due to bleed (€7631)
and secondly by transfusions (€114) and laboratory tests (€91).
CONCLUSION: Haemorrhagic complications associated with
hospitalized ACS patients showed a marked increase in the
mean resources use and operating costs of this patient popula-
tion in Spain.
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